We believe that retail sales for toy airplanes will peak from March to midMay, after which water toys will dominate. For E-Chargers, we've been fortunate to have secured a sizable amount of shelf space in retail stores for this period and also have been awarded several large feature endcap orders! To meet this demand, we have to have 20,000 units ready to ship by December 1999 as shown in this schedule [see Exhibit I]. On top of the fact that the retailers need time to move our product through their distribution system, we've heard that a major competitor, a large toy company, is also working on the same E-Chargers concept. We have to beat them to market at all costs because, in this industry, it is hard to overcome the first mover advantage. While we would like to have a five- to six-month design-to-delivery window, we have four months, max. But we also have to consider the tight tolerances we require. Our initial work revealed that we have to be very careful to balance weight shaving and structural integrity. Ideally, an E-Charger should weigh 17 grams. An increase of only one gram decreases the flying time by 15 seconds. Just painting the plane adds enough weight to affect the performance significantly. According to our preliminary tests, the plane will weigh 18 grams, and we have to work tremendously hard to reduce that figure. At 18.5 grams, this thing won't even fly

61 I want to ask something about cerebrovascular accident (CVA). Can you please tell me how we can rapidly pinpoint the exact anatomical site of the neurological deficit using physical findings in the emergency room?

62 Why do you treat dissection of the carotid artery with an anticoagulant in the acute management of stroke secondary to dissection? To me this seems paradoxical as it would increase the severity of dissection.

63 Last week, in a neurology viva, I was asked about the indications for heparinization in patients with a stroke. I want to know when I can stop heparin and what test I should use for assessing its therapeutic range.

64 Has heparin a role in the management of acute ischaemic stroke not accompanied by atrial fibrillation?

65 1. In the treatment of a stroke, does low-molecular-weight heparin (LMWH) have an advantage over heparin? 2. In an ischaemic stroke in evolution, for how long should heparin be administered?

66 Can streptokinase be used in acute cerebral infarction and, if so, what is the dose?

67 There seems now to be a consensus about starting aspirin therapy in acute ischaemic strokes as early as possible. Why has this changed from past recommendations to avoid aspirin early (during the first 48 hours) during the ischaemic stroke on the pretext that it could convert an ischaemic infarct into a haemorrhagic one, thus increasing the dangers of complications like cerebral oedema and raised intracranial pressure? If both opinions are based on clinical trials, what is the significance of the much hyped 'evidence-based medicine'?

68 I understand that a loading dose of clopidogrel 600-900 mg can be given to ischaemic stroke in evolution and can stop the evolving deficit. Would you agree?

69 Is there any rationale for giving patients with recurrent strokes a combination of aspirin and anticoagulant?

70 1. Does a dipyridamol-aspirin combination have any superiority over aspirin alone in the secondary prevention of a stroke? 2. Is an aspirin plus anticoagulant combination superior to a dipyridamol aspirin combination in the treatment of recurrent ischaemic stroke not controlled by aspirin alone?